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Summary Delayed-type hypersensitivity (DTH) to Rauscher murine leukaemia virus (R-MuLV) encoded or
induced determinants was induced in mice by three syngeneic R-MuLV-induced tumour cell lines, i.e. a
myeloid tumour, RMB-1, an erythroid tumour, RED-1, and a lymphoid tumour, RLD-1. DTH to
subcutaneously (s.c.) administered RMB-1 cells appeared on day 4, with a maximum DTH response on day 6
or 7. The induction of DTH could be prevented by intravenous (i.v.) pre-immunisation with R-MuLV-
induced tumour cells several days before the s.c. immunisation. The three R-MuLV-induced tumour cell lines
showed cross-reactivity in the DTH assay, whereas no cross-reactivity was found with syngeneic WEHI-3
cells. This indicates that the three R-MuLV-induced tumour cell lines share a virally encoded or induced
antigenic determinant, which activates T-cells. When the RMB-1 cells used for immunisation had been
cultured in medium supplemented with interferon-y (IFN-y), the subsequent DTH response was increased.
This coincided with an increased expression of the R-MuLV-specific antigenic determinants on RMB-1 cells
as demonstrated by Scatchard analysis. Furthermore, IFN-y increased the MHC class I antigen expression on
RMB-1 cells, whereas the class II antigen expression remained undetectable.
Immunological tumour-rejection depends on the presence of
antigenic determinants on the tumour cells, which are not
usually present on their normal counterparts. Such antigenic
determinants may be induced by chemical, viral or physical
agents and can also be found on spontaneously arising
tumours (Halliday & Webb, 1969; Morton et al., 1969;
Kripke, 1981; Galetto et al., 1985). Cells transformed by
RNA tumour viruses express virally encoded proteins, and
so-called virus associated proteins (Nowinski, 1978; Rogers
et al., 1984). These neoantigens can induce antibody
formation as well as cellular immune responses, such as
cellular cytotoxicity and delayed-type hypersensitivity (DTH)
(Levy & Leclerc, 1977).
DTH responses can be easily elicited to various antigens,
such as bacteria, viruses, xenogeneic red blood cells and
contact sensitising _agents (reviewed by Crowle, 1975).
Tumour cells can also induce DTH (Halliday & Webb, 1969;
Hawrylko, 1980; Hoover et al., 1984). DTH reactions are
mediated by T-cells, particularly by the L3T4 positive helper
T-cell subset (Mosmann & Coffman, 1987). Evidence is
increasing that Lyt-1 2-, L3T4+ T-cells, depending on the
experimental conditions, can also mediate tumour rejection
(Ozawa et al., 1986; Paul et al., 1987; Bookman et al., 1987).
Several adjuvants have been used to increase the anti-
tumour response, such as BCG (Hawrylko, 1980) and
Corynebacterium parvum (Dye et al., 1981). One could also
increase the anti-tumour response by enhancing the
immunogenicity of the tumour, for instance by using
haptenated tumour cells (Suda et al., 1986) or by treatment
with interferon, which is known to increase the expression of
MHC-encoded antigens (Tanaka et al., 1986).
In previous studies we reported about two R-MuLV-
specific monoclonal antibodies (MAbs) raised against a R-
MuLV-induced myeloid tumour (Berends et al., 1988a,b, c).
One of the MAbs, which recognises virally encoded proteins
on RMB-1 cells, was successfully used in immunotherapy. A
striking difference was found between the effect of this MAb
therapy in T-cell deprived nude mice and their euthymic
littermates. This led us to suggest that a T-cell dependent
anti-tumour immune response is involved (Berends et al.,
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1989). Infiltration analysis of tumour foci in the liver of
treated euthymic mice revealed equal numbers of L3T4+ and
Lyt-2+ T-cells. However, a striking infiltrate of macrophages
was present in the tumour foci of the euthymic mice. Since
sensitised helper T-cells produce macrophage attracting
factors, they might play an important role in the activation
and influx of macrophages in the tumour foci and
subsequently in tumour destruction. Since such activities are
characteristic for DTH reactions, we studied whether
R-MuLV-induced tumour cells indeed induced DTH in syn-
geneic mice.
After having established that R-MuLV-induced tumour
cells indeed evoke DTH, we investigated the specificity of
this response, its suppression after i.v. pre-immunisation with
irradiated tumour cells, and the effect of interferon-y (IFN-y)
on the expression of the R-MuLV-induced tumour cell
surface antigens and on the immunogenicity of RMB-1 cells
as measured in the DTH assay.
Materials and methods
Mice
BALB/c (H-2d) and DBA/2 (H-2d) female mice, 4 weeks of
age, were purchased from Bomholtgard (Ry, Denmark).
BALB/c (H-2d) female mice, 4 weeks of age, were purchased
from Harlan Olac Ltd (Bicester, UK). Other BALB/c (H-2d)
female and male mice were bred at the Department of Cell
Biology, Immunology and Genetics of the Erasmus
University.
Cell lines
Three R-MuLV-induced tumour cell lines were used: a
myeloid tumour cell line of BALB/c origin (RMB-1), a
lymphoid tumour cell line of DBA/2 origin (RLD-1), and an
erythroid tumour cell line of DBA/2 origin (RED-1) (De
Both et al., 1978, 1981, 1983, 1985). The WEHI-3 immature
macrophage cell line of BALB/c origin, originally described
by Warner et al. (1969), was used as a control. This cell line
does not express R-MuLV antigens. All cell lines were
cultured in RPMI 1640 tissue culture medium, supplemented
with 10% fetal calf serum, glutamin (4mM), penicillin
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(lOOIUml-1) and streptomycin (l00 gml-1), in a
humidified atmosphere with 5% CO2. IFN-y was supplied
by Drs M. van Heuvel and I.J. Bosveld as culture
supernatant from a Chinese hamster cell line with the
amplified murine recombinant IFN-y gene (Dijkmans et al.,
1985) containing 3 x 104IUml-1. As a control culture
supernatant from the CHO12RO cell line was used (Stefanini
et al., 1982). When IFN-y was added to the tissue culture
medium, it was supplemented to a final concentration of
100-150IUml-1.
Antigen density on RMB-J cells
To quantitate the density of a R-MuLV-encoded surface
antigen of RMB-1 cells, a Scatchard analysis was performed,
using the specific MAb 1C5F5 that was previously described
(Berends et al., 1988a). Briefly, RMB-1 cells were incubated
for 90min at room temperature in a volume of 100 1l of
Hanks' balanced salt solution (HBSS), supplemented with
20mM HEPES and 0.125% gelatin containing varying
amounts (0.01-lOnM) of 125I-1C5F5. lodination of the
MAbs was earlier described (Berends et al., 1988b). For the
determination of non-specifically bound 1251C5F5, the cells
were incubated with varying amounts of 125I-1C5F5 in the
presence of excess (10-6 M) unlabelled 1C5F5 for 90min.
Thereafter the cells were washed to remove unbound
1C5F5. Cell-bound radioactivity was determined in an LKB
1280 ultra-gammacounter. The association constant (Ka) and
the number of binding sites were calculated according to
Scatchard (1949).
FACScan analysis
MHC class I and class II expression of RMB-1 cells,
cultured in the presence or absence of IFN-y, was
determined as earlier described (Van Ewijk et al., 1981). The
MAbs Ml/42 (Springer, 1980) and M5/114 (Bhattacharya et
al., 1981) that were used for the detection of class I and class
II molecules, respectively, were kindly provided by the group
of Dr W. van Ewijk. As a control RMB-1 cells were
incubated with normal mouse serum (NMS). At least 5 x 103
cells from each individual sample were analysed using a
flow-cytofluorometer (FACScan, Becton Dickinson,
Mountain View, CA, USA).
Induction of DTH reactivity
DTH was induced by s.c. immunisation of the mice with
3 x 107 irradiated (20Gy) tumour cells suspended in a
volume of 300pl. A volume of 150M1 of this suspension was
injected into each inguinal area.
Assay for DTH
DTH responses were elicited by s.c. injection of 3-6 x 106
irradiated (20Gy) tumour cells, suspended in a volume of
50 u1, into the dorsum of the right hind foot 7 days after the
induction of DTH. Unimmunised control mice received this
challenge only. The difference in thickness of the right and
left hind foot was measured 24h later. The specific DTH
response was calculated as- the relative increase in foot
thickness of the immunised mice minus the relative increase
in foot thickness of the control mice. The increase of foot
thickness of the control mice generally ranged between 10
and 20%.
Induction of suppression
Suppression of DTH was induced by i.v. administration of a
high dose of heavily irradiated (80Gy) tumour cells, 7 days
before the induction of DTH. The administered number of
cells is indicated in the legend to the figures.
Data analysis
For the statistical analysis of the significance of differences
observed, P values were calculated by Student's t test. Values
of P less than 0.05 were considered significant. In Figures 1
and 3, P values were calculated in comparison with the
increase of foot thickness of the control mice. In Figures 4
and 6 the P values were calculated in comparison with the
specific increase of foot thickness of the relevant (positive)
control group.
Results
Induction ofDTH reactivity to R-MuLV-induced tumour cells
BALB/c responder mice were s.c. immunised with varying
doses of syngeneic RMB-1 cells. A maximal DTH response
was found after s.c. immunisation with 3 x 107 RMB-I cells
(data not shown). This dose was used during all the
experiments described. DBA/2 responder mice were s.c.
immunised with 3 x 107 syngeneic RED-1 or RLD-1 tumour
cells. Seven days after s.c. immunisation all mice were
challenged with 6 x 106 similar tumour cells as used for
immunisation. The RMB-1 cell line induced a pronounced
DTH response P<0.05, whereas the responses induced by
RED-1 and RLD-1 cells were reproducible although not
significant, P=0.05 (Figure 1).
Kinetics of the DTH response to RMB-J cells
Several groups of BALB/c responder mice were s.c.
immunised with 3 x 107 RMB-1 cells. At various days after
immunisation, individual groups were challenged with
3 x 106 RMB-1 cells. From day 4 after immunisation DTH
was detectable with a maximum response around day 7
(Figure 2).
Cross-reactivity between tumour-associated antigens on
different R-MuLV-induced cell lines
To investigate whether the DTH reactive T-cells responding
to the R-MuLV-induced tumour cell lines recognise a
common (presumably viral) determinant we investigated the
cross-reactivity in the DTH assay. Thus, BALB/c mice were
s.c. immunised with 3 x 107 RMB-1 cells and challenged for
DTH 7 days later with 6x 106 RMB-1, RED-1 or RLD-1
cells. As a control groups of BALB/c mice were challenged
with 6 x 106 DBA/2 spleen cells or with WEHI-3 cells.
Figure 3 shows that after immunisation with RMB-1 cells
challenge with each of the three tumour cell lines led to a
substantial DTH response, P<0.05 (lines 1-3). Challenge
with DBA/2 spleen cells or with the WEHI-3 cell line,
however, did not cause a DTH response suggesting the
absence of cross-reactivity with non-H-2 alloantigens or
other neoantigens not induced by the R-MuLV (lines 4 and
5). Cross-reactivity between the three R-MuLV-induced
tumour cell lines was also found after s.c. immunisation of
DBA/2 responder mice with 3 x 107 RED-1 or RLD-1 cells
responder s.C. challenge % specific increase
strain immunisation of foot thickness
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Figure 1 DTH reactivity to RMB-1, RED-1 and RLD-1
tumour cells. BALB/c mice were s.c. immunised with 3 x 107
RMB-1 cells and challenged for DTH with 6 x 106 RMB-1 cells 7
days later. DBA/2 responder mice were s.c. immunised with
3 x 107 RED-1 or RLD-1 cells and challenged for DTH 7 days
later with 6 x 106 RED-I and RLD-l cells, respectively. Each
column represents the arithmetic mean of the response+ 1 s.e.m.
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Figure 2 Kinetics of the DTH response to RMB-1 cells.
BALB/c mice were s.c. immunised with 3 x 107 RMB-1 cells.
DTH reactivity was determined at various intervals after s.c.
immunisation. Each experimental point represents the arithmetic
mean of the response+ 1 s.e.m. (n=5).
and challenge with RMB-1 cells, P<0.05 (lines 6 and 7),
whereas no DTH was found after challenge with BALB/c
spleen cells (lines 8 and 9). Cross-reactivity was also
determined after s.c. immunisation with RED-1 cells and
challenge with RLD-1 cells and vice versa, P<0.05 (lines 10
and 11).
Suppression of DTH to RMB-1 cells
After i.v. injection of BALB/c responder mice with either
1 x 107 or 5 x 107 irradiated RMB-1 tumour cells, s.c.
immunisation with 3x 107 RMB-1 tumour cells no longer
induced a state of DTH, P<0.05 (Figure 4). The suppression
was found independent of whether or not the RMB-1 cells
had been treated with IFN-y. Previous studies have shown
that such an i.v. pre-immunisation induces suppressor T (Ts)
cells, which can suppress the subsequent induction or
elicitation of DTH (Van der Kwast et al., 1981; Bianchi et
al., 1984).
Effect of IFN-y on antigen-expression and DTH reactivity
IFN-y is known for its enhancing effect on the expression of
various antigens. We studied the effect of IFN-y on the
expression of R-MuLV-induced antigens. To this end IFN-y
was added to the culture medium of RMB-1 cells for 24 or
48h. Stimulation of RMB-1 cells with IFN-y for 24h caused
a nearly two-fold increase in the amount of binding sites on
RMB-1 cells detected by the binding of 1251-labelled-IC5F5
(Figure 5a), and a slight decrease in affinity (Figure Sb). This
coincided with a strong enhancement of DTH, P<0.05
(Figure 6). After culture of RMB-l cells with IFN-y for 48h
the increase in R-MuLV antigen-expression was much
smaller than in RMB-1 cells that had been cultured with
IFN-y for 24h. In this case also no enhancing effect in the
DTH assay was found. Apparently the IFN-y induced
increased expression of R-MuLV-encoded proteins by
RMB-1 cells is only temporary. This increased antigen-
expression was not due to an increase in the cell size (data
not shown).
MHC class I and class II antigen expression
Since it is possible that the enhanced DTH response is
(partly) due to an increased MHC antigen expression on
RMB-1 cells, we also studied the MHC class I and class II
antigen expression, using the monoclonal antibodies Ml/42
(anti-H-2K) and M5/114 (anti-H-21-A). From Figure 7 it is
clear that class I antigens are constitutively expressed by
RMB-1 cells (Figure 7a), whereas class II antigens are not
(Figure 7b). Moreover, after culturing RMB-1 cells for 24h
in the presence of IFN-y, class I antigen expression was
clearly enhanced, whereas class II antigen expression
remained undetectable.
Discussion
This study shows that R-MuLV-induced tumour cell lines
induce DTH in syngeneic mice. This T-cell dependent
response is pronounced in the case of RMB-1 cells. The
weak DTH responses evoked by RED-1 and RLD-1 cells
were not significant above the background level, although
they were highly reproducible. This correlates with the fact
that the latter two cell lines differ from the RMB-1 cell line
in that they are virus-producing, whereas RMB-1 is not.
Moreover, RMB-1 cells grow s.c. only after inoculation of
high numbers of cells whereas RED-1 and RLD-1 cells do
even after s.c. inoculation of low numbers (unpublished
results).
The maximum DTH response to RMB-1 cells was found 7
days after s.c. immunisation. This is in accordance with
reports by others (Hawrylko et al., 1980). DTH responses to
histocompatibility antigens generally peak one or two days
earlier.
All three different R-MuLV-induced cell lines could induce
DTH, although the responses were not equally strong. We
investigated whether DTH induced by s.c. immunisation with
one cell line could be elicited by challenge with another R-
MuLV-induced cell line. Cross-reactivity was found in all
combinations tested. The response was highest when RMB-1
cells were used for immunisation or challenge. The cross-
reactivity between RED-1 and RLD-1 cells was relatively
weak, as could be expected in view of the weak DTH
responses these cell lines evoke. Together the results suggest
that the DTH response is directed to a common R-MuLV-
encoded or induced tumour-associated antigen, most clearly
expressed on RMB-1 cells.
Even if tumours possess immunogenic determinants they
can escape elimination by the immune system. The
mechanisms involved could be the release of suppressive
factors by the tumour cells (Mizel et al., 1980), or the
induction of suppressor cells (for a review see North, 1985).
Here we report the induction of suppression of the
subsequent DTH response, by administration of a high dose
of heavily irradiated tumour cells. Most probably the huge
amount of tumour antigens leads to the induction of the
state of suppression. Previously we investigated extensively
the mechanism of suppression of the DTH response to H-2
and non-H-2 histocompatibility antigens after i.v. pre-
immunisation, which proved to be due to the induction of Ts
cells. These Ts cells were found to be specific for the
antigen(s) used for their induction (Van der Kwast et al.,
1981; Bianchi et al., 1984). Despite this possibility of
induction of antigen-specific Ts cells, it should be taken into
account that factors released by the (irradiated) tumour cells
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Figure 3 Cross-reactivity of tumour-associated antigens on RMB-1, RED-1 and RLD-1 cells. Several groups of BALB/c mice
were s.c. immunised with 3 x 107 RMB-l cells and challenged for DTH with 6 x 106 RMB-1, RED-1 or RLD-1 cells. Control mice
were challenged with 6 x 106DBA/2 spleen cells or WEHI-3 cells. DBA/2 responder mice were s.c. immunised with 3 x 107 RED-1
or RLD-l cells and challenged for DTH with 6 x 106 RMB-1 cells. A DBA/2 control group was challenged with 6 x 106 BALB/c
spleen cells. All cell lines had been cultured with IFN-y for the last 24h. Each column represents the arithmetic mean of the
response+ 1 s.e.m. (n =5).
responder i.v. s.c. immunisation treatment of % specific increase
strain pre-immunisation and challenge immunising cells of foot thickness
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Figure 4 Induction of a state of suppression by i.v. administration of RMB-1 cells. BALB/c mice were i.v. pre-immunised with
either 1 or 5 x 107 RMB-1 cells. In one experiment the RMB-1 cells used had been cultured with IFN-y for 24h, in the other
untreated RMB-1 cells were used. Seven days after i.v. pre-immunisation all mice were s.c. immunised with 3 x 107 RMB-l cells.
Another 7 days later the mice were challenged with 6 x 106 RMB-1 cells. Each column represents the arithmetic mean of the
response+ 1 s.e.m. (n =5).
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Figure 5 Determination of the number of binding sites and the association constant (K.) of '251-labelled 1C5F5 MAbs on
RMB-1 cells by Scatchard analysis. a, A constant number (4 x 105) of RMB-1 cells was incubated with varying amounts (0.01-
10nM) of 125I-IC5F5. For the determination of non-specifically bound 1251-1C5F5, the cells were incubated with excess (106M)
unlabelled lC5F5 for 90min, Bmax is the number of binding sites under saturated conditions. b, Ka was calculated by the quotient
of 1251-1C5F5-bound/1251-1C5F5-free as compared to the amount of 1251-1C5F5-bound. 0, untreated RMB-1 cells; Bmax 180,000
cell-l; Ka 7.4x 108lmol-'. 0, RMB-1 cells cultured with IFN-y for 24h; Bmax 335,0000 cell-'; Ka 4.2x 108lmol-'. A, RMB-1
cells cultured with IFN-y for 48 h; Bmax 218,000 cell-'; Ka 3.6 x 108 imol-'
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Figure 6 Effect of IFN-y on the immunogenicity of RMB-1 cells. BALB/c mice were s.c. immunised with 3 x 107 RMB-1 cells
that had been cultured with IFN-y for 24 or 48h. As a control mice were immunised with RMB-l cells that had been cultured in
the absence of IFN-y. Seven days later all mice were challenged for DTH with 6 x 106 similar RMB-1 cells. Each column
represents the arithmetic mean of the response+ 1 s.e.m. (n=5).
might also give rise to the immunosuppression. The
retroviral protein p15E should particularly be mentioned in
this respect (Bendinelli et al., 1985).
When suppression can be induced by a huge amount of
tumour antigens presented to the immune system, this
phenomenon might play a role in clinical practice, since
irradiation is frequently used in the therapy of malignant
tumours, which leads to massive tumour reduction, and
therefore to the appearance of large. amounts of tumour-
derived antigens in the bloodstream. This in turn could lead
to suppression of the induction of an adequate immune
response.
One approach to achieving tumour rejection is to prevent
or block a possible immunosuppressive mechanism.
Alternatively one might enhance the host's anti-tumour
response using adjuvants, such as BCG (Hawrylko, 1980)
and Corynebacterium parvum (Dye et al., 1981). A third way
would be the enhancement of tumour immunogenicity. Suda
et al. (1986) reported increased anti-tumour immunity using
haptenated tumour cells.
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Figure 7 FACScan analysis of RMB-1 cells. a, MHC class I
expression determined using the MAb MI/42. ---- RMB-1 cells
cultured with IFN-y for 24h, incubated with NMS as a control;
RMB-1 cells cultured in the absence of IFN-y, stained with
the MAb MI/42; ..... RMB-1 cells cultured with IFN-y for 24h,
stained with the MAb MI/42. b, MHC class II expression
determined using the MAb M5/114. ---- RMB-1 cells cultured
with IFN-y for 24h, incubated with NMS as a control;
RMB-1 cells cultured in the absence of IFN-y, stained with the
MAb M5/114; .-- RMB-1 cells cultured with IFN-y for 24h,
stained with the MAb M5/114.
Here we show that IFN-y can temporarily enhance the
expression of tumour-specific antigens. Interestingly, in
parallel the in vivo anti-tumour DTH response was enhanced
(Figure 6). On one hand, the enhanced DTH response could
be caused by the increased expression of R-MuLV-encoded
antigens. On the other hand, it is also possible that the
increased MHC class I antigen expression accounts for the
increased DTH response, since the immune recognition of
syngeneic tumour cells may be MHC class I restricted
similarly to DTH to minor histocompatibility antigens (Van
der Kwast, 1980).
Various authors asked attention for the
immunomodulating effects of interferons (for reviews see
Krim, 1980; De Maeyer-Guignard & De Maeyer, 1985).
Interferons should exert their"effects via at least three
mechanisms, i.e. direct cytotoxicity, increased MHC antigen
expression on the tumour cells and increased host-mediated
anti-tumour effects. Most studies on the effect of interferons
on tumour immunogenicity focus on the increase of the
expression of MHC antigens on the tumour cells (King &
Jones, 1983; Green & Philips, 1986). We found increased
MHC class I antigen expression on the RMB-1 cells after
culture with IFN-y, whereas class II antigen expression
remained absent. The present study shows that IFN-y in
addition enhances the expression of a. virally encoded or
induced tumour antigen. A similar finding has recently been
reported by Greiner et al. (1987). They demonstrated the
increased expression of a tumour-associated antigen on a
human colon-xenograft after treatment with IFN-a.
Accumulation of immature viral budding particles at the cell
surface due to inhibitory action of IFN-a/f has been
described before (Friedman et al., 1980). Possibly, the
effectiveness of MAb therapy of tumours can be improved
by simultaneous treatment with a tumour antigen-enhancing
lymphokine such as interferon.
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